[1]
Pipi E, Marketou M, Tsirogianni A. Distinct clinical and laboratory characteristics of latent autoimmune diabetes in adults in relation to type 1 and type 2 diabetes mellitus. World J Diabetes 2014; 5(4): 505-10.
[2]
Ostergaard JA, Laugesen E, Leslie RD. Should there be concern about autoimmune diabetes in adults? Current evidence and controversies. Curr Diab Rep 2016; 16(9): 82.
[3]
Laugesen E, Østergaard JA, Leslie RD. Danish Diabetes Academy Workshop and Workshop Speakers. Latent autoimmune diabetes of the adult: Current knowledge and uncertainty. Diabet Med 2015; 32(7): 843-52.
[4]
Kumar A, de Leiva A. Latent autoimmune diabetes in adults (LADA) in Asian and European populations. Diabetes Metab Res Rev 2017; 33(5)
[5]
Muazu SB, Okpe I, Anumah F. The prevalence and characteristics of latent autoimmune diabetes in adults subset among type two diabetes mellitus patients in Northern Nigeria. Ann Afr Med 2016; 15(4): 163-70.
[6]
Maddaloni E, Lessan N, Al Tikriti A, Buzzetti R, Pozzilli P, Barakat MT. Latent autoimmune diabetes in adults in the united arab emirates: clinical features and factors related to insulin-requirement. PLoS One 2015; 10(8): e0131837.
[7]
Schwartz SS, Epstein S, Corkey BE, Grant SF, Gavin JR III, Aguilar RB. The time is right for a new classification system for diabetes: rationale and implications of the beta-cell-centric classification schema. Diabetes Care 2016; 39(2): 179-86.
[8]
Brophy S, Davies H, Mannan S, Brunt H, Williams R. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst Rev 2011; 9: CD006165.
[9]
Leslie RD, Palmer J, Schloot NC, Lernmark A. Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia 2016; 59(1): 13-20.
[10]
Fourlanos S, Dotta F, Greenbaum CJ, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005; 48(11): 2206-12.
[11]
Hawa MI, Buchan AP, Ola T, et al. LADA and CARDS: A prospective study of clinical outcome in established adult-onset autoimmune diabetes. Diabetes Care 2014; 37(6): 1643-9.
[12]
Clauson P, Linnarsson R, Gottsäter A, Sundkvist G, Grill V. Relationships between diabetes duration, metabolic control and beta-cell function in a representative population of type 2 diabetic patients in Sweden. Diabet Med 1994; 11(8): 794-801.
[13]
Ludvigsson J. The clinical potential of low-level C-peptide secretion. Expert Rev Mol Diagn 2016; 16(9): 933-40.
[14]
Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26(3): 832-6.
[15]
Sjöberg S, Gunnarsson R, Gjötterberg M, Lefvert AK, Persson A, Ostman J. Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30(4): 208-13.
[16]
Buzzetti R, Pozzilli P, Frederich R, Iqbal N, Hirshberg B. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes Metab Res Rev 2016; 32(3): 289-96.
[17]
Jones AG, McDonald TJ, Shields BM, et al. Markers of beta-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care 2016; 39(2): 250-7.
[18]
Thunander M, Thorgeirsson H, Törn C, Petersson C, Landin-Olsson M. Beta-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: A 3-year follow-up. Eur J Endocrinol 2011; 164(2): 239-45.
[19]
Brophy S, Davies H, Dunseath G, et al. Experience of the introduction of routine antibody testing in primary care and of running a trial for latent autoimmune diabetes in adults (LADA). Diabetes Res Clin Pract 2011; 93(1): e49-52.
[20]
Andersen CD, Bennet L, Nyström L, et al. Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy. Diabetologia 2013; 56(2): 252-8.
[21]
Sørgjerd EP, Skorpen F, Kvaløy K, Midthjell K, Grill V. Time dynamics of autoantibodies are coupled to phenotypes and add to the heterogeneity of autoimmune diabetes in adults: The HUNT study, Norway. Diabetologia 2012; 55(5): 1310-8.
[22]
Gale EA. Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 2005; 48(11): 2195-9.
[23]
Thrasher J. Pharmacologic management of type 2 diabetes mellitus: available therapies. Am J Cardiol 2017; 120(1S): S4-S16.
[24]
Itariu BK, Stulnig TM. Autoimmune aspects of type 2 diabetes mellitus - a mini-review. Gerontology 2014; 60(3): 189-96.
[25]
Shimada A, Shigihara T, Okubo Y, Katsuki T, Yamada Y, Oikawa Y. Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes. Diabetes Metab Res Rev 2011; 27(8): 951-3.
[26]
Radtke MA, Midthjell K, Nilsen TI, Grill V. Heterogeneity of patients with latent autoimmune diabetes in adults: linkage to autoimmunity is apparent only in those with perceived need for insulin treatment: Results from the Nord-Trondelag Health (HUNT) study. Diabetes Care 2009; 32(2): 245-50.
[27]
Agardh CD, Lynch KF, Palmér M, Link K, Lernmark A. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 2009; 52(7): 1363-8.
[28]
Zhao Y, Yang L, Xiang Y, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains beta-cell function in patients with recent-onset latent autoimmune diabetes in adults: One year prospective study. J Clin Endocrinol Metab 2014; 99(5): E876-80.
[29]
Awata T, Shimada A, Maruyama T, et al. Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (spiddm) in the stage of non-insulin-dependency: An open-label randomized controlled pilot trial (SPAN-S). Diabetes Ther 2017; 8(5): 1123-34.
[30]
Maruyama T, Tanaka S, Shimada A, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 2008; 93(6): 2115-21.
[31]
Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: A randomised, double-blind, non-inferiority trial. Lancet 2012; 380(9840): 475-83.
[32]
Johansen OE, Boehm BO, Grill V, et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care 2014; 37(1): e11-2.
[33]
Pozzilli P, Leslie RD, Peters AL, et al. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials. Diabetes Obes Metab 2018; 20(6): 1490-8.
[34]
Poudel RR. Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin. Indian J Endocrinol Metab 2012; 16(Suppl. 1): S41-6.
